These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

124 related articles for article (PubMed ID: 24092052)

  • 1. Bayesian approach to estimate AUC, partition coefficient and drug targeting index for studies with serial sacrifice design.
    Wang T; Baron K; Zhong W; Brundage R; Elmquist W
    Pharm Res; 2014 Mar; 31(3):649-59. PubMed ID: 24092052
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Comparison of methods for the estimation of carboplatin pharmacokinetics in paediatric cancer patients.
    Peng B; Boddy AV; Cole M; Pearson AD; Chatelut E; Rubie H; Newell DR
    Eur J Cancer; 1995 Oct; 31A(11):1804-10. PubMed ID: 8541105
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Comparison of tenofovir plasma and tissue exposure using a population pharmacokinetic model and bootstrap: a simulation study from observed data.
    Collins JW; Heyward Hull J; Dumond JB
    J Pharmacokinet Pharmacodyn; 2017 Dec; 44(6):631-640. PubMed ID: 29119381
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Estimation of AUC from 0 to Infinity in Serial Sacrifice Designs.
    Wolfsegger MJ; Jaki T
    J Pharmacokinet Pharmacodyn; 2005 Dec; 32(5-6):757-66. PubMed ID: 16328101
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Restricted brain penetration of the tyrosine kinase inhibitor erlotinib due to the drug transporters P-gp and BCRP.
    de Vries NA; Buckle T; Zhao J; Beijnen JH; Schellens JH; van Tellingen O
    Invest New Drugs; 2012 Apr; 30(2):443-9. PubMed ID: 20963470
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Maximum a posteriori Bayesian estimation of mycophenolic Acid area under the concentration-time curve: is this clinically useful for dosage prediction yet?
    Staatz CE; Tett SE
    Clin Pharmacokinet; 2011 Dec; 50(12):759-72. PubMed ID: 22087863
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Review and Validation of Bayesian Dose-Optimizing Software and Equations for Calculation of the Vancomycin Area Under the Curve in Critically Ill Patients.
    Turner RB; Kojiro K; Shephard EA; Won R; Chang E; Chan D; Elbarbry F
    Pharmacotherapy; 2018 Dec; 38(12):1174-1183. PubMed ID: 30362592
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Limited sampling models and Bayesian estimation for mycophenolic acid area under the curve prediction in stable renal transplant patients co-medicated with ciclosporin or sirolimus.
    Musuamba FT; Rousseau A; Bosmans JL; Senessael JJ; Cumps J; Marquet P; Wallemacq P; Verbeeck RK
    Clin Pharmacokinet; 2009; 48(11):745-58. PubMed ID: 19817503
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Pharmacokinetics of low-dose carboplatin and applicability of a method of calculation for estimating individual drug clearance.
    Etienne MC; Leger F; Pivot X; Chatelut E; Bensadoun RJ; Guardiola E; Renée N; Magné N; Canal P; Milano G
    Ann Oncol; 2003 Apr; 14(4):643-7. PubMed ID: 12649114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Comparison of the Bayesian approach and a limited sampling model for the estimation of AUC and Cmax: a computer simulation analysis.
    Mahmood I; Miller R
    Int J Clin Pharmacol Ther; 1999 Sep; 37(9):439-45. PubMed ID: 10507242
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effect of two priors on Bayesian estimation of "Proper" binormal ROC curves from common and degenerate datasets.
    Zur RM; Pesce LL; Jiang Y
    Acad Radiol; 2010 Aug; 17(8):969-79. PubMed ID: 20605491
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A limited sampling strategy for estimation of the area under the plasma concentration-time curve of gefitinib.
    Miura M; Sato K; Miura H; Niioka T; Kobayashi H; Narita C; Ito H
    Ther Drug Monit; 2014 Feb; 36(1):24-9. PubMed ID: 24413624
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Pharmacokinetic study of the phase III, randomized, double-blind, multicenter trial (TRIBUTE) of paclitaxel and carboplatin combined with erlotinib or placebo in patients with advanced Non-small Cell Lung Cancer (NSCLC).
    Tran HT; Zinner RG; Blumenschein GR; Oh YW; Papadimitrakopoulou VA; Kim ES; Lu C; Malik M; Lum BL; Herbst RS
    Invest New Drugs; 2011 Jun; 29(3):499-505. PubMed ID: 20094773
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Population pharmacokinetics of ciclosporin in haematopoietic allogeneic stem cell transplantation with emphasis on limited sampling strategy.
    Wilhelm AJ; de Graaf P; Veldkamp AI; Janssen JJ; Huijgens PC; Swart EL
    Br J Clin Pharmacol; 2012 Apr; 73(4):553-63. PubMed ID: 21988410
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Validation of techniques for the prediction of carboplatin exposure: application of Bayesian methods.
    Huitema AD; Mathôt RA; Tibben MM; Schellens JH; Rodenhuis S; Beijnen JH
    Clin Pharmacol Ther; 2000 Jun; 67(6):621-30. PubMed ID: 10872644
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The relative bioavailability of gefitinib administered by granular formulation.
    Cantarini MV; Bailey CJ; Collins B; Smith RP
    Cancer Chemother Pharmacol; 2008 Jul; 62(2):203-8. PubMed ID: 17909808
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Comparison of neural network, Bayesian, and multiple stepwise regression-based limited sampling models to estimate area under the curve.
    Ng CM
    Pharmacotherapy; 2003 Aug; 23(8):1044-51. PubMed ID: 12921250
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Pharmacokinetic study of mycophenolate mofetil in patients with systemic lupus erythematosus and design of Bayesian estimator using limited sampling strategies.
    Zahr N; Amoura Z; Debord J; Hulot JS; Saint-Marcoux F; Marquet P; Piette JC; Lechat P
    Clin Pharmacokinet; 2008; 47(4):277-84. PubMed ID: 18336056
    [TBL] [Abstract][Full Text] [Related]  

  • 19. A comparison of Bayesian and non-linear regression methods for robust estimation of pharmacokinetics in DCE-MRI and how it affects cancer diagnosis.
    Dikaios N; Atkinson D; Tudisca C; Purpura P; Forster M; Ahmed H; Beale T; Emberton M; Punwani S
    Comput Med Imaging Graph; 2017 Mar; 56():1-10. PubMed ID: 28192761
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Plasma and cerebrospinal fluid pharmacokinetics of erlotinib and its active metabolite OSI-420.
    Broniscer A; Panetta JC; O'Shaughnessy M; Fraga C; Bai F; Krasin MJ; Gajjar A; Stewart CF
    Clin Cancer Res; 2007 Mar; 13(5):1511-5. PubMed ID: 17332296
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.